What’s new at the FDA?
- Ed Silverman at Pharmalot reports on FDA plans to spend some of its user-fee money on post-marketing safety activities.
- Merrill Goozner at GoozNews warns that the FDA is scrapping the Helsinki Declaration on protecting human subjects.
- Jacob Goldstein at WSJ’s Health Blog wonders whether pharmaceutical groups’ proposals to pay user fees to fund inspections of foreign drug factories is a good idea.
Roy M. Poses MD at Health Care Renewal describes a terrible lack of conflict-of-interest disclosure in an NPR program on antidepressants.
Elizabeth Cooney at White Coat Notes highlights concerns about conflicts of interest among panelists for the psychiatric diagnostic manual DSM.
Kate Sheppard at Gristmill reports on a Senate subcommittee hearing from which EPA administrator Stephen Johnson was conspicuously absent. (The Pump Handle’s own David Michaels testified at that hearing; his testimony is here.)
Amanda at Enviroblog has the details about oil companies’ settlements of lawsuits involving the gasoline additive MTBE.
Matt Madia at Reg Watch considers the federal agencies that could regulate bisphenol A – but probably won’t get around to it this year.
Revere at Effect Measure explains how and why the USDA is trying to stop a company from testing its cattle for mad cow disease.